Ron Sabo

909 total citations
22 papers, 740 citations indexed

About

Ron Sabo is a scholar working on Endocrinology, Diabetes and Metabolism, Oncology and Epidemiology. According to data from OpenAlex, Ron Sabo has authored 22 papers receiving a total of 740 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Oncology and 4 papers in Epidemiology. Recurrent topics in Ron Sabo's work include Diabetes Treatment and Management (11 papers), Peptidase Inhibition and Analysis (4 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Ron Sabo is often cited by papers focused on Diabetes Treatment and Management (11 papers), Peptidase Inhibition and Analysis (4 papers) and Pharmacogenetics and Drug Metabolism (3 papers). Ron Sabo collaborates with scholars based in United States, France and Switzerland. Ron Sabo's co-authors include Monica Ligueros‐Saylan, Joelle Campestrini, William P. Dole, Dan Howard, Yanling He, Yibin Wang, Margaret Salfi, Paul Glue, Samir K. Gupta and C Raffanel and has published in prestigious journals such as Hepatology, Journal of Allergy and Clinical Immunology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Ron Sabo

21 papers receiving 688 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ron Sabo United States 13 352 197 197 182 174 22 740
Hans Ditschuneit Germany 18 155 0.4× 250 1.3× 293 1.5× 476 2.6× 112 0.6× 26 950
Takefumi Kimura Japan 22 217 0.6× 317 1.6× 932 4.7× 343 1.9× 99 0.6× 102 1.5k
Yücel Batur Türkiye 19 157 0.4× 98 0.5× 566 2.9× 307 1.7× 83 0.5× 64 1.0k
S. Galastri Italy 13 92 0.3× 161 0.8× 426 2.2× 150 0.8× 86 0.5× 17 790
Irsan Hasan Indonesia 17 120 0.3× 225 1.1× 581 2.9× 144 0.8× 82 0.5× 96 906
R Enat Israel 15 128 0.4× 204 1.0× 304 1.5× 294 1.6× 80 0.5× 42 965
Liangsu Wang United States 14 156 0.4× 234 1.2× 258 1.3× 241 1.3× 149 0.9× 25 731
Jianwei Zhang China 18 49 0.1× 184 0.9× 71 0.4× 238 1.3× 261 1.5× 79 912
Seren Özeni̇rler Türkiye 18 115 0.3× 116 0.6× 473 2.4× 116 0.6× 54 0.3× 51 762
Yoichi Koizumi Japan 17 295 0.8× 238 1.2× 39 0.2× 259 1.4× 84 0.5× 29 848

Countries citing papers authored by Ron Sabo

Since Specialization
Citations

This map shows the geographic impact of Ron Sabo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron Sabo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron Sabo more than expected).

Fields of papers citing papers by Ron Sabo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ron Sabo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron Sabo. The network helps show where Ron Sabo may publish in the future.

Co-authorship network of co-authors of Ron Sabo

This figure shows the co-authorship network connecting the top 25 collaborators of Ron Sabo. A scholar is included among the top collaborators of Ron Sabo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ron Sabo. Ron Sabo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jarugula, Venkateswar, et al.. (2011). Pharmacokinetics and Pharmacodynamics of Aliskiren/Hydrochlorothiazide Single‐Pill Combination Tablets and Free Combination of Aliskiren and Hydrochlorothiazide. The Journal of Clinical Pharmacology. 52(5). 645–655. 3 indexed citations
2.
Khindri, Sanjeev, Ron Sabo, Stephen Harris, Simon Jennings, & Anton Drollmann. (2009). A Thorough QT Study on the Effect of Indacaterol on Cardiac Safety in Healthy Subjects.. A2463–A2463. 4 indexed citations
3.
He, Yanling, Ron Sabo, Joelle Campestrini, et al.. (2007). The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. European Journal of Clinical Pharmacology. 63(7). 677–686. 58 indexed citations
4.
He, Yanling, Ron Sabo, Joelle Campestrini, et al.. (2007). The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers. British Journal of Clinical Pharmacology. 65(3). 338–346. 56 indexed citations
5.
Sunkara, Gangadhar, Ron Sabo, Yibin Wang, et al.. (2007). Dose Proportionality and the Effect of Food on Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, in Healthy Volunteers. The Journal of Clinical Pharmacology. 47(9). 1152–1158. 38 indexed citations
6.
He, Yanling, Ron Sabo, Gangadhar Sunkara, et al.. (2007). Evaluation of Pharmacokinetic Interactions Between Vildagliptin and Digoxin in Healthy Volunteers. The Journal of Clinical Pharmacology. 47(8). 998–1004. 33 indexed citations
7.
He, Yanling, Ron Sabo, Gilles‐Jacques Rivière, et al.. (2007). Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Current Medical Research and Opinion. 23(5). 1131–1138. 33 indexed citations
8.
He, Yanling, Brian M. Sadler, Ron Sabo, et al.. (2007). The Absolute Oral Bioavailability and??Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers. Clinical Pharmacokinetics. 46(9). 787–802. 64 indexed citations
9.
He, Yanling, Monica Ligueros‐Saylan, Gangadhar Sunkara, et al.. (2007). Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions With the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects. The Journal of Clinical Pharmacology. 48(1). 85–95. 38 indexed citations
10.
He, Yanling, et al.. (2006). PIII-16Lack of pharmacokinetic interaction between Vildagliptin and Metformin in patients with type 2 diabetes. Clinical Pharmacology & Therapeutics. 79(2). P62–P62. 11 indexed citations
11.
He, Yanling, et al.. (2006). PIII-19The influence of age, gender and BMI on the pharmacokinetics and pharmacodynamics of vildagliptin. Clinical Pharmacology & Therapeutics. 79(2). P63–P63. 8 indexed citations
12.
He, Yanling, et al.. (2006). PII-12Absolute bioavailability of vildagliptin in healthy subjects. Clinical Pharmacology & Therapeutics. 79(2). P38–P38. 13 indexed citations
13.
Sabo, Ron, et al.. (2003). Poisoning with acetylcholinesterase inhibitors in dogs: two case reports. Veterinární Medicína. 48(6). 175–176. 6 indexed citations
14.
Banfield, Christopher, et al.. (2003). Desloratadine suppresses histamine- and allergen-induced cutaneous wheal and flare responses in allergic subjects during 6 months' treatment. Journal of Allergy and Clinical Immunology. 111(2). S235–S235. 1 indexed citations
15.
Glue, Paul, Régine Rouzier‐Panis, C Raffanel, et al.. (2000). A Dose-Ranging Study of Pegylated Interferon Alfa-2b and Ribavirin in Chronic Hepatitis C. Hepatology. 32(3). 647–653. 185 indexed citations
16.
Huhn, Richard D., Kenneth J. Pennline, Elaine Radwanski, et al.. (1999). Effects of single intravenous doses of recombinant human interleukin-10 on subsets of circulating leukocytes in humans. Immunopharmacology. 41(2). 109–117. 15 indexed citations
17.
Huhn, Richard D., et al.. (1997). Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers*. Clinical Pharmacology & Therapeutics. 62(2). 171–180. 104 indexed citations
18.
Schenker, Steven, et al.. (1997). Activity and Tolerance of a Continuous Subcutaneous Infusion of Interferon-α2b in Patients with Chronic Hepatitis C. Journal of Interferon & Cytokine Research. 17(11). 665–670. 9 indexed citations
19.
Glue, Paul, David L. Cutler, Ron Sabo, et al.. (1996). Pharmacodynamic Effects of Interferon ALFA-2b in Healthy Volunteers. Clinical Pharmacology & Therapeutics. 59(2). 205–205. 1 indexed citations
20.
Lassman, Howard B., et al.. (1988). Pharmacokinetics of Roxithromycin (RU 965). The Journal of Clinical Pharmacology. 28(2). 141–152. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hans Ditschuneit Breakdown of academic impact, for papers by Takefumi Kimura Breakdown of academic impact, for papers by Yücel Batur Breakdown of academic impact, for papers by S. Galastri Breakdown of academic impact, for papers by Irsan Hasan Breakdown of academic impact, for papers by R Enat Breakdown of academic impact, for papers by Liangsu Wang Breakdown of academic impact, for papers by Jianwei Zhang Breakdown of academic impact, for papers by Seren Özeni̇rler Breakdown of academic impact, for papers by Yoichi Koizumi
Rankless by CCL
2026